Scholarlink

<p>The expression of somatostatin receptors (SSTRs) represents a key biological characteristic of neuroendocrine tumors (NETs) and serves as the basis for theranostics (i.e., the combination of therapy and diagnostics). To this end, somatostatin analogues are radioactively labelled with the relevant isotopes for use in both diagnostics and therapy (peptide receptor radionuclide therapy, PRRT). PRRT using the radiopharmaceutical <sup>177</sup>lutetium-DOTA-Tyr<sup>3</sup>-octreotate (<sup>177</sup>Lu-DOTATATE) is an effective and well-established treatment for metastatic, well-differentiated gastroenteropancreatic NETs, having been approved on the basis of the NETTER-1&#xa0;trial. For patients in whom the disease progresses after PRRT, new therapeutic approaches, such as α‑therapeutic procedures involving <sup>225</sup>Ac-labelled ligands, offer promising prospects. Additionally, selective internal radiotherapy (SIRT) is an alternative option for patients with predominant hepatic metastasis. Current studies are also examining complementary therapy concepts, such as combining PRRT with systemic therapy (e.g., chemotherapy or immunomodulators).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nuklearmedizinische Therapien bei neuroendokrinen Tumoren

  • 期刊论文

  • 发表日期：

    2025年10月7日

查看全文
  • Sophie C. Siegmund,
  • Christoph J. Auernhammer,
  • Alexander Weich,
  • Rudolf A. Werner

摘要

The expression of somatostatin receptors (SSTRs) represents a key biological characteristic of neuroendocrine tumors (NETs) and serves as the basis for theranostics (i.e., the combination of therapy and diagnostics). To this end, somatostatin analogues are radioactively labelled with the relevant isotopes for use in both diagnostics and therapy (peptide receptor radionuclide therapy, PRRT). PRRT using the radiopharmaceutical 177lutetium-DOTA-Tyr3-octreotate (177Lu-DOTATATE) is an effective and well-established treatment for metastatic, well-differentiated gastroenteropancreatic NETs, having been approved on the basis of the NETTER-1 trial. For patients in whom the disease progresses after PRRT, new therapeutic approaches, such as α‑therapeutic procedures involving 225Ac-labelled ligands, offer promising prospects. Additionally, selective internal radiotherapy (SIRT) is an alternative option for patients with predominant hepatic metastasis. Current studies are also examining complementary therapy concepts, such as combining PRRT with systemic therapy (e.g., chemotherapy or immunomodulators).